Brower Piven, A Professional Corporation on Mar. 18 announced that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Geron Corporation (NASDAQ:GERN) securities during the period between June 16, 2013 and March 11, 2014, inclusive (the “Class Period”). Geron Corporation (NASDAQ:GERN) stock performance was -8.06% in last session and finished the day at $2.28. Traded volume was 12,319,989 million shares in the last session and the average volume of the stock remained 6.27 million shares. The beta of the stock remained 1.82. Geron Corporation (NASDAQ:GERN) insider ownership is 0.10%.

OXiGENE Inc (NASDAQ:OXGN) on Mar. 11 announced positive results from a randomized Phase 2 clinical trial evaluating Avastin(R) (bevacizumab) with or without ZYBRESTAT(R) (fosbretabulin; CA4P) to treat patients with recurrent ovarian cancer. OXiGENE Inc (NASDAQ:OXGN) dropped -7.73 percent to $3.70 yesterday on volume of 3.38 million shares. The intra-day range of the stock was $3.66 to $4.15. OXiGENE Inc (NASDAQ:OXGN) has a market capitalization of $ 42.43 million.

Opexa Therapeutics Inc. (NASDAQ:OPXA) reported financial results for the year ended Dec. 31, 2013, and provided an overview of recent corporate developments. During the year ended December 31, 2013, Opexa reported revenue of $1,266,611 related to the $5 million upfront payment from Merck in connection with the Option and License Agreement. Opexa Therapeutics Inc (NASDAQ:OPXA)’s stock on Mar19, 2014 reported a decrease of -7.83% to the closing price of $2.00. Its fifty two weeks range is $1.25 -$3.70. The total market capitalization recorded $55.09 million. The overall volume in the last trading session was 1,542,018 million shares. In its share capital, Opexa Therapeutics Inc (NASDAQ:OPXA) has 14.72 million outstanding shares.

22nd Century Group, Inc. (OTCQB:XXII) announced that its wholly owned subsidiary, Goodrich Tobacco Company, has been granted a federal permit to produce tobacco products by the Alcohol and Tobacco Tax and Trade Bureau of the U.S. Department of the Treasury (“TTB Permit”).On Wednesday, shares of 22nd Century Group Inc (NYSEMKT:XXII) dropped -12.87% to close the day at $3.79. Company return on investment (ROI) is 23.40% and its monthly performance is recorded as 15.55%. 22nd Century Group Inc (NYSEMKT:XXII) quarterly revenue growth is 136.87%.